Open access peer-reviewed chapter

Functional Analysis of the Cervical Carcinoma Transcriptome: Networks and New Genes Associated to Cancer

Written By

Mauricio Salcedo, Sergio Juarez-Mendez, Vanessa Villegas-Ruiz, Hugo Arreola, Oscar Perez, Guillermo Gómez, Edgar Roman-Bassaure, Pablo Romero, Raúl Peralta

Submitted: November 27th, 2010 Reviewed: June 16th, 2011 Published: September 2nd, 2011

DOI: 10.5772/23551

Chapter metrics overview

2,960 Chapter Downloads

View Full Metrics

1. Introduction

Cancer is one of the most important public health problem in Mexico and worldwide, especially for female population, breast and cervical cancer (CC) types are the most frequent. Incidence rates of CC are higher in developing countries 40/100,000 women per year vs. 10/100,000 in developed countries (1). In Mexico there are 12,000 new reports cases every year (2). The absence of the screening programs or comparatively ineffective screening programs lead to relatively late diagnosis of the disease and also in differences in the human papillomavirus (HPV) infection (3). Several types of HPV are associated with CC worldwide (4, 5), being the HPV16 the most frequent oncogenic type.

Epidemiological and experimental studies suggest that high risk HPV have an important role in cervical carcinogenesis. Persistent viral infection, genetic background in combination with constitutive expression of the viral oncogenes as E6 and E7, are decisive steps for malignant transformation, because these oncoproteins interact with the tumour suppressor proteins p53 and pRB, respectively for their degradation (6, 7). Finally, these interactions could induce cellular proliferation and genetic instability for example, which could promote the accumulation of mutations and aneuploidy (8). In conclusion, viral oncoproteins have a general impact in global profile of expressed genes, which could be analyzed by high-throughput methodologies. One of these techniques is DNA oligonucleotide-based microarray technology, which allows a rapid and high-throughput detection of thousands of transcripts simultaneously (9- 11).

It has been published several studies about gene expression profiles in HPV infected cells. Mainly these reports are based on gene expression levels altered by E6 and E7 HPV oncoproteins (12- 17). Regarding changes in gene expression profiles in cervical cancer samples, there are a few papers comparing normal cervical expressed genes versus tumors samples (12, 18), the major aim in those studies was to find potential tumor markers with clinical value. At present the list of the potential markers is short (p16, survivin).

We have published some works about alterations in gene expression in CC (19, 20). In those reports we observed that WNT pathway, calcium pathway and some cellular proteases (MMP11, cathepsin F) could be involved in cervical carcinogenesis. Thus, these findings are contributing to our knowledge about alterations in CC pathogenesis.

In the present work our microarray data obtained from microarray assay on CC samples (20) were newly managed and analyzed by using new bioinformatics suite programs and then, to get others genes altered in cervical cancer, as well as to define signaling pathways probably implicated in this type of cancer.

Advertisement

2. Material and methods

Biological samples. Eight squamous CC tissues stage IIB (according of International Federation of Obstetrics and Gynecology, FIGO) HPV16 positive were selected and two healthy “normal” cervical samples were originally studied. The normal samples were collected after hysterectomy by uterine myomatosis without HPV infection history. All DNAs from healthy and cervical cancer samples were subjected to PCR by using general oligonucleotides against to HPV; and to confirm the HPV type, the positive samples were then sequenced (data not shown). An important point to eliminate negative false, only the samples harboured at least 70% of tumour cells or normal epithelial cells were analyzed.

Total RNA was extracted from squamous CC and normal tissues using TRIzol reagent (GIBCO, BRL, USA). RNA was synthesized and labeled with CodeLink Express Assay Reagent Kit (Applied Microarrays, GE Healthcare, USA).

2.1. Microarray platform

CodeLink™ Human Whole Genome Microarrays offer comprehensive coverage of the Human genome, this array have ~57,000 probes and consider transcripts and ESTs (expression tagged sequences). In this system are included: 1,200 genes for oncogenesis process, 1,400 for cell cycle, 1,000 for cell-signaling, 3,000 for metabolism, 1,400 for developmental process, 2,700 of transcription and translation, 1,100 for immune and inflammation response, 800 for protein phosphorylation, 600 for apoptosis, 1,150 for ion transport, 400 for synaptic transmission, 200 for kinases, among other.

This array harbors 45,674 genes (based on unique UniGene IDs), 360 positive controls, 384 negative controls, 100 housekeeping genes, one specific and functionally validated probe and the oligonucleotide probe length of 30-mer.

This platform has been applied in different biological models (21-23). CodeLink Bioarray are recently introduced, single-color oligonucleotide microarrays, which differ from Affymetrix GeneChips in the following aspects: 1) this Bioarray use a single pre-synthesized, pre-validated 30-mer probe to detect each target transcript, whereas Gene-Chips use multiple in-situ synthesized, 25-mer probes; and 2) the surface of CodeLink Bioarrays is made of 3-dimensional aqueous gel matrix, whereas that of Affymetrix GeneChips is made of 2-dimensional glass matrix. These characteristics could suggest that CodeLink Bioarrays behave differently from GeneChips and may require different normalization strategies from the ones optimized for GeneChips (24)(Figure 1).

Figure 1.

General strategy of microarray analysis on cervical cancer samples. Originally RNA samples from normal epithelial cells or CC lesions were subjected to hybridization reaction on arrays. The data were analyzed by using different bioinformatics Tools to obtain differentially expressed genes.

Advertisement

3. Analysis of the data

Partek® Genomics SuiteTM is a comprehensive suite of advanced statistics and interactive data visualization specifically designed to reliably extract biological signals from noisy data. The commercial software is unique in supporting all microarray and next generation sequencing technologies including gene expression and digital gene expression, exon/alternative splicing, RNA-Seq, copy number and association, ChIP-chip, ChIP-seq, and microRNAs in a single software package, allowing for analysis of multiple applications in one complete solution.

This kind of analysis will provide results with minimal noises generated from the internal controls. To perform this analysis is necessary to apply a software suite which is composed by three different statistical tests: Probe Statistical algorithm (MAS5), Probe Logarithmic Intensity Error (Plier) and Robust Multichip Analysis (RMA). The goal of these tests is to establish differences and similarities between internal controls and to get the most real data. In the present case, the normalized samples were analyzed RMA statistical tests eliminating the tags harboring variations.

In the global gene expression is difficult understand what happen with all of genes in different cellular process including the cancer, in this context a way of visualization data is a Principal Component Analysis or PCA (25). This method is a mathematical technique to reduction the effect of the gene expression sample in a small dimensional space, when there is less changes in the global gene expression the dimensional is smaller. Next for visualization of changes in gene expression in all samples we made a clustering analysis (26), in this method we used a K-means algorithm and let to classify to determine similitude and dissimilitude in all samples, to finish we applied methods of systems biology as Ingenuity Pathway Analysis) and gene classification to determine new list of candidates for subsequent lab verification and might help in the search for a cure for cancers.

3.1. Networks by Ingenuity Pathways Analysis (IPA)

This software (www.ingenuity.com) to help life science researchers explore, interpret, and analyze complex biological Systems, and is used to help researchers analyze 'omics data and model biological systems. This analysis was to identify Networks of interacting genes and other functional groups. A cut-off ratio of 2 was used to define genes.

Advertisement

4. Results

The best and most accurate method for identifying disease-causing genes is monitoring gene expression values in different samples using microarray technology. One of the shortcomings of microarray data is that they provide a small quantity of samples with respect to the number of genes. This problem reduces the classification accuracy of the methods, so gene selection is essential to improve the predictive accuracy and to identify potential marker genes for a disease. Among numerous existing methods for gene selection, PARTEK has become one of the leading methods, but its performance can be reduced because of the small sample size, noisy data and the fact that the methods remove redundant genes.

The original cervical dataset was already published and available in a previous report (20). This dataset was obtained by using CodeLink microarray platform and provides the expression levels of 57,000 probes for 2 normal tissues and 8 cervical cancers HPV16 positive. The data were pre-processed by carrying out a base 10 logarithmic transformation and normalized (see Figure 2). After first analysis of the data, using significance analysis of microarrays 3,248 genes well annotated were identified.

After that, the data already normalized were managed and analyzed using Partek genomics suite version 6.5 (Partek GS) obtaining a list of differentially expressed genes (Tumor versus Normal). Specific and new procedures are actually performed in analysis of microarray data. For instance, after internal control analysis, the raw data are normalized using the common software available on line or some other like Partek GS. This suite provides rigorous and easy-to-use statistical tests for differential expression of genes or exons, and a flexible and powerful statistical test to detect alternative splicing based on a powerful mixed model analysis of variance.

By one-side ANOVA statistical test a small group of 208 genes were selected with a false discovery ratio < 10%, from these, 111 overexpressed genes with a fold change >2, and 97 downregulated genes with a fold change of <-2 genes were observed (Tables 1 and 2).

Figure 2.

Normalization data set. The values of gene expression were normalyzed by medians. A) Left image is showing the normalization of positive internal controls harboured in the bioarray. The right image is showing the normalization of negative internal controls of the array. As example, these figures corresponds to a normal samples.

Table 1.

List of genes and EST’s (without gene name) up-regulated

Table 1b.

List of genes up-regulated

Table 2.

List of genes and EST’s (without gene name) down-regulated

Table 2b.

List of genes down-regulated

4.1. Analyzing microarray data with novel software suite

If we want to display the data in just two dimensions, we want as much of the variation in the data as possible captured in just two dimensions. Principal component analysis or PCA has been developed for this purpose. Applying this PCA method in the cervical data we observed some expected differences (Figure 3).

Figure 3.

Principal component analysis of cervical cancer samples. As expected, after perform PCA analysis, the normal samples (red balls) were grouped out of CC Group (blue balls) in a 3-D image.

In order to obtain a graphical representation of the differences between normal and tumor tissues, hierarchical cluster analysis was performed on all samples with a pseudo-color visualization matrix of the 208 selected genes grouping with greater intra-group similarity and differences between groups. The phylogenetic tree resulting from the hierarchical complete linkage-clustering algorithm is shown in figure 4. The figure shows those genes that are changing respect to health cervical tissue. In this method of clustering, allows to do relationships among objects (genes or samples) and are represented by a tree whose branch lengths reflect the degree of similarity between the objects, as assessed by a pairwise similarity function. The computed trees can be used to arrange individual samples in the original data table; this allows the samples or groups of samples with similar expression patterns to be shown adjacent to each other.

In general, tumor samples showed heterogeneity among them compared with normal samples, which had a more homogeneous gene expression profile. So, clustering analysis in CC failed to show significant segregation of patients based on expression profiling possibly

Figure 4.

Hierarchical clustering of the gene expression data for cervical tissues. Clustering analysis were performed for all tumours and normal samples. The data were clustered using the standard hierarchical method with ward linkage and using the Perason correlation to determine distance tumour. Before clustering, the data was filtered to remove genes that were scored absent in 75% or more of the samples as they are likely to be measuring noise in the system. The cluster of normal samples exhibit nearly identical patterns of gene expression changes, on contrary, as expected the invasive samples grouped in a different branch showing a heterogeneous gene expression. Blue color indentify downregulation and red color an overexpression status.

due to the heterogeneous nature of the samples as well as the relatively small numbers of samples in this study. Even when the samples were subjected to rigorous procedures of analysis, the special selection of the patients, including age, clinical stage, HPV16 positive and contraceptive oral status avoiding any bias, in this stage of the carcinogenesis process (stage IIb) the pattern of gene expression is quite different between samples.

Table 3.

Disease and Disorders functions in cervical cancer

We used IPA to investigate the biological relevant of the observed genome-wide expressed gene changes by categorizing our data set into biological functions and/or diseases Ingenuity Pathway analysis was applied. The 208 genes annotated list by PARTEK analysis was submitted to the visualization IPA tool. This bioinformatics tool is employed for visualizing expression data in the context of KEGG biological pathways; the importance IPA is that retrieves an impact factor (IF) of genes that entire pathway involved, which can help to obtain a clearer notion of the alteration level in each biological pathway, and understand the complexity of these different process of the cancer cell. We imported a list of significantly up and down regulated genes (with extension.txt) into the program to convert the expression data into illustrations in an attempt to explore altered mechanisms in CC. To overcome any possible incorrect IF in altered pathways due to different size of samples, we submitted a similar quantity of up and down regulated genes. This allowed confirming that genes involved in several metabolic pathways were altered in CC (see networks).

We were able to associate biological functions and diseases to the experimental results. Fifteen pathways were obtained with a high score. Table 3 is showing the genes and the top three disorders/disease of “small networks” based in the analysis of the data. As can be seen, a clear route in cancer as it is known was not observed but some genes have been previously associated; however, these data give important information involving “non canonical”pathways in cancer.

Finally, in the Figure 5 is showed a “hypothetical network in CC” based from the 15 small networks. In addition to gene expression values, the proposed method uses Gene Ontology, which is a reliable source of information on genes. The use of Gene Ontology can compensate, in part, for the limitations of microarrays, such as having a small number of samples and erroneous measurement results.

Advertisement

5. Discussion

In our results, non classical “cancer genes” were conserved, respect to expected genes as MYC, FOS, RB, P53, HIF, etc. However, in the “strict sense of the word” when is considered a cancer gene? By instance, over-expression, down-regulation, point mutation, amplification, loss of heterozygosity, polymorphisms, epigenetic changes, etc. Thus, any gene could be considered like cancer gene, if they are following special criteria as recently was reported (27).

In this context, we decided to explore two non-related genes in cervical cancer PARK2gene. Interestingly, PARK2gene mutations (point mutations and exonic deletions) were first identified in autosomal recessive juvenile-onset parkinsonism. This gene is mapped to 6q25.2-q27 containing 12 small exons, and encodes parkin protein which functions as an E3 ligase, ubiquitinating proteins for destruction by the proteosome. Several substrates for parkin have been identified, including a 22kD glycosolated form of synuclein, parkin-associated endothelin receptor-like receptor (Pael-R), and CDCrel-1. Over-expression of Pael-R causes it to become ubiquinated, insoluble, and unfolded, and lead to endoplasmic reticulum stress and cell death (for review see 28). The location of Parkin is in a chromosomal region that is frequently deleted in multiple tumor types, including hepatocellular carcinoma (HCC), ovarian cancer, and breast cancer. The Parkin gene is within FRA6E, the third most active common fragile site (29,30). Interestingly, all three fragile sites regions were found consistently deleted in HCC (31) as well as in ovarian, breast, and prostate cancers. Further PARKIN protein overexpression did not lead to

Figure 5.

Networks in cervical cancer. Top three networks diagrams generated as graphical representations of the molecular relationship between genes and gene product. The gene products are represented as nodes (shapes) and the biological relationship between two nodes is represented as an edge (line). A) Network 1. skeletal and muscular system development and function, embryonic development, tissue development, B) network 2; dermatological diseases and conditions, cardiovascular disease, organismal injury and abnormalities, C) network 3; cell cycle, organismal functions, organismal injury and abnormalities, D) Ingenuity Pathways Analysis network of genes associated with CC. This network diagram shows the biological association of 8 focus networks associated with cervical cancer as graphical representation of the molecular relationship between genes/gene produtcs.

increased sensitivity to all pro-apoptotic induction but may show specificity for a certain type of cellular stress. At present, Parkingene could be considered as new tumor suppressor gene (32). In our case, per seParkin expression in CC is interesting. It is widely described that p53 master gene is constitutively expressed but under stress conditions as HPV infection, DNA damage or point mutations its half-time life of the protein is increased. Similar situation might be observed for Parkingene due to increased expression in CC. This could be supported because the 6q25 cytogenetic region in CC is not altered as happen for TP53gene (33). To this respect, we could hypothesize that a new overexpression of Parkingene could be involved in invasion cervical carcinogenesis. These findings could demonstrate that the genetic context in which a mutation occurs can play a significant role in determining the type of illness produced or associated.

It has been established that although we inherit two copies of all genes (except those that reside on the sex chromosomes), there is a subset of these genes in which only the paternal or maternal copy is functional. This phenomenon of monoallelic, parent-of-origin expression of genes is termed genomic imprinting. Imprinted genes are normally involved in embryonic growth and behavioral development, but occasionally they also function inappropriately as oncogenes and tumor suppressor genes (34). Furthermore, it is well know that a variety of genetic changes influence the development and progression of cancer. These changes may result from inherited or spontaneous mutations that are not corrected by repair mechanisms prior to DNA replication. It is increasingly clear that so called epigenetic effects that do not affect the primary sequence of the genome also play an important role in tumorigenesis (35).

Other gene overexpressed seen in this analysis was PEG10gene. This gene is mapped in chromosme 7q21. PEG10 protein prevents apoptosis in hepatocellular carcinoma cells through interaction with SIAH1, a mediator of apoptosis. May also have a role in cell growth promotion and hepatoma formation. Inhibits the TGF-beta signaling by interacting with the TGF-beta receptor ALK1. This is a paternally expressed imprinted gene that encodes transcripts containing two overlapping open reading frames (ORFs), RF1 and RF1/RF2, as well as retroviral-like slippage and pseudoknot elements, which can induce a -1 nucleotide frame-shift. Increased expression of this gene is associated with hepatocellular carcinomas. These findings link to cancer genetics and epigenetic by showing that a classic proto-oncogene, MYC, acts directly upstream of a proliferation-positive imprinted gene, PEG10 (36,37).

The HOXgenes are a family of transcription factors that bind to specific sequences of DNA in target genes regulating their expression. The role of HOXgenes in adult cell differentiation is still obscure, but growing evidence suggests that they may play an important role in the development of cancer. We have previously reported that some HOXgenes could be related to CC. Specifically, HOXA9was observed expressed in cervical cancer by RT-PCR end point. In the present work, the data are showing that statistically significative HOXA9gene is differentially expressed in CC. Together to HOXB13, D9, D10, and HOXCcluster (HOXC9, C11–C13) genes this family of genes might be an important factor involved in CC (35).

It is clear that the most altered genes in CC are not commonly associated to cancer process. This fact could suggest: 1) the “classic genes of cancer” are statistically significant altered with tiny values, but there are some exceptions and specific tumor types as neuroblastomas and N-MYCgene, Her2/neuin breast cancer. 2) At least in stage IIb of cervical carcinogenesis could be involved genes related to “cellular economy” but not belonging to genes of cancer. This is supported by recent reports showing molecular alterations in genes not previously related to cancer (27). 3) The extreme values (high or low) in microarray analysis not always represent strong candidates of markers in the models performed. What about the most frequent?. (4) Integrative genomics, multicentre protocols in well selected samples, stratified stages and clinical follow-up, will be the clue to get cancer hallmarks. In addition, the study of the molecular function of selected genes strengthened the hypothesis that these genes are involved in the process of cancer growth.

The data information obtained from microarray analysis should be validated because can appear errors in positive and negative false due to nature of the massive assays. In this context, in order to confirm the microarray data, additional molecular tool as end point PCR, real time PCR, northern blot, immunohistochemistry should be performed and to obtain results. (Mendez S. An Integrative microarray gene expression analysis, approach identifies candidates’ array multi-experiments in Ovary Tumours, submitted to publication 2011).

Advertisement

Acknowledgments

This work was partially supported by CONACYT (México) grants 69719 AND 87244 from FONDOS SECTORIALES. We appreciate the technical assistance of Laboratorio de Oncología Genómica, CIS, HO-IMSS. Sergio JUAREZ and Mauricio SALCEDO made similar efforts in the present work.

References

  1. 1. Parkin DM, Bray F, Ferlay J, Pisani P.Global cancer statistics, 2002. CA Cancer J Clin.2005, 55(2):74-108
  2. 2. Secretaría de Salud (Méx).Registro Histopatológico de Neoplasias en México. México: Secretaría de Salud, México D.F;1999
  3. 3. MunozN.XavierBosch. F.Cervical cancer and human papillomavirus: epidemiological evidence and perspectives for prevention. Salud Publica Mex199739274282
  4. 4. BoffettaP.ParkinD. M.Cancer in developing countries. CA Cancer J Clin199419944481
  5. 5. WalboomersJ. M.JacobsM. V.MMManosBosch. F. X.KummerJ. A.ShahK.et al.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol1999
  6. 6. ScheffnerM.WernessB. A.HuibregtseJ. M.LevineA. J.HowleyP. M.The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell1990
  7. 7. BoyerS. N.WazerD. E.BandV. E.E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway.Cancer Res.1996
  8. 8. DuensingS.MungerK.The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res.2002
  9. 9. Nees M, van Wijngaarden E, Bakos E, Schneider A, Dürst M.Identifcation of novel molecular markers which correlate with HPVinduced tumor progression. Oncogene1998, 16:2447-2458
  10. 10. BrownP.BotsteinR.Exploring the new world of the genome with DNA microarrays. Nature Genet1999suppl):3337
  11. 11. Lockhart DJ, Winzeler EA.Genomics, gene expression and DNA arrays.Nature,2000
  12. 12. RuutuM.PeitsaroP.JohanssonB.SyrjanenS.Transcriptional profiling of a human papillomavirus 33-positive squamous epithelial cell line which acquired a selective growth advantage after viral integration. Int J Cancer2002
  13. 13. Duffy CL, Phillips SL, Klingelhutz AJ: Microarray analysis identifies differentiation-associated genes regulated by human papillomavirus type 16 E6.Virol2003
  14. 14. ThomasJT, Oh ST, Terhune SS, Laimins LA: Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. J Virol2001
  15. 15. Garner-HamrickP. A.FostelJ. M.ChienW. M.BanerjeeN. S.ChowL. T.BrokerT. R.FisherC.Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte culture system. J. Virol2004
  16. 16. Toussaint-SmithE.DonnerD. B.RomanA.Expression of human papillomavirus type 16 E6, E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene2004
  17. 17. NeesM.GeogheganJ. M.HymanT.FrankS.MillerL.WoodworthC. D.Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated, NF-kappaB-responsive genes in cervical keratinocytes. J Virol2001
  18. 18. ShimC.ZhangHun. C.LeeProfiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. Clin Cancer Res1998
  19. 19. Vazquez-OrtizG.GarcíaJ. A.CiudadC. J.NoéV.PeñuelasS.López-RomeroR.Mendoza-LorenzoP.Piña-SánchezP.SalcedoM.MDifferentially expressed genes between high-risk human papillomavirus types in human cervical cancer cells. Int J Gynecol Cancer.2007
  20. 20. Pérez-PlasenciaC.Vázquez-OrtizG.López-RomeroR.Piña-SanchezP.MorenoJ.SalcedoM.Genome wide expression analysis in HPV16 cervical cancer: identification of altered metabolic pathways. Infect Agent Cancer.2007
  21. 21. DavidsonL. A.NguyenD. V.HokansonR. M.CallawayE. S.IsettR. B.TurnerN. D.DoughertyE. R.WangN.LuptonJ. R.CarrollR. J.ChapkinR. S.Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Res.2004
  22. 22. RamakrishnanR.DorrisD.LublinskyA.NguyenA.DomanusM.ProkhorovaA.GieserL.ToumaE.LocknerR.TataM.ZhuX.PattersonM.ShippyR.SenderaT. J.MazumderA.An assessment of Motorola CodeLink microarray performance for gene expression profiling applications. Nucleic Acids Res.2002e30.
  23. 23. NieA. Y.Mc MillianM.ParkerJ. B.LeoneA.BryantS.YiehL.BittnerA.NelsonJ.CarmenA.WanJ.LordP. G.Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog.2006
  24. 24. WuW.DaveN.TsengG.RichardsT.XingE. P.KaminskiN.Comparison of normalization methods for CodeLink Bioarray data. BMC Bioinformatics2005
  25. 25. ReichD.PriceAl.PatttersonN.Principal component analysis of genetic data. Nature Genetics.2008
  26. 26. EisenM. B.SpellmanP. T.BrownP. O.BotsteinD.Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A1998
  27. 27. MJSeltzerBennett.BDJoshiA. D.GaoP.ThomasA. G.FerrarisD. V.TsukamotoT.RojasC. J.BSSlusherRabinowitz.JDDangC. V.RigginsG. J.Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res.2010
  28. 28. SchapiraA.Etiology of Parkinson’s disease Neurol2006S10S23
  29. 29. KahkonenM.Population cytogenetics of folate-sensitive fragile sites. Common fragile sites. Hum Genet1988
  30. 30. DenisonS. R.WangF.MuellerB.KockN.PhillipsL. A.KleinC.SmithD. I.Genetic alteration in the common fragile site gene PARK2 in ovarian and other cancers. Oncogene2003
  31. 31. ZhaoP.SongX.NinY. Y.LuY. L.LiX. H.Loss of fragile histidine triad protein in human hepatocellular carcinoma. World J Gastroenterol2003
  32. 32. WangF.DenisonS.LaiJ. P.PhilipsL. A.MontoyaD.KockN.SchuleB.KleinC.ShridharV.RobertsL. R.SmithD.Parkin Gene Alterations in Hepatocellular Carcinoma. Genes Chromosome & cancer2004
  33. 33. HidalgoA.BaudisM.PetersenI.ArreolaH.PiñaP.VazquezG.HernandezD.GonzalezJ. L.LazosM.LopezR.SalcedoM.Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer2005
  34. 34. Jirtle RL.Genomic imprinting and cancer. Exp Cell Res.1999
  35. 35. Plass C, Soloway PD.DNA methylation, imprinting and cancer. Eur J Hum Genet2002, 10:6-16
  36. 36. LiC. M.AAMargolinSalas. M.MemeoL.MansukhaniM.HibshooshH.SzabolcsM.KlinakisA.TyckoB.PEG10 Is a c-MYC Target Gene in Cancer Cells.Cancer Cells. Cancer Res2006
  37. 37. TsujiK.PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet,2010In press.
  38. 38. LópezR.GarridoE.VázquezG.PiñaP.PérezC.AlvaradoI.A subgroup of HOX Abd-B gene is differentially expressed in cervical cancer.Int J Gynecol Cancer.2006

Notes

  • , , , , , , ,

Written By

Mauricio Salcedo, Sergio Juarez-Mendez, Vanessa Villegas-Ruiz, Hugo Arreola, Oscar Perez, Guillermo Gómez, Edgar Roman-Bassaure, Pablo Romero, Raúl Peralta

Submitted: November 27th, 2010 Reviewed: June 16th, 2011 Published: September 2nd, 2011